Outcomes and Risk Factors Associated with Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents
Top Cited Papers
- 27 June 2011
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 118 (10), 2028-2034
- https://doi.org/10.1016/j.ophtha.2011.02.034
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Ranibizumab for Macular Edema following Branch Retinal Vein OcclusionOphthalmology, 2010
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Ranibizumab for Macular Edema following Central Retinal Vein OcclusionOphthalmology, 2010
- TOXIC VITREITIS OUTBREAK AFTER INTRAVITREAL INJECTIONRetina, 2010
- Endophthalmitis After Anti-VEGF InjectionsOphthalmology, 2009
- INFECTIOUS ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTIANGIOGENIC AGENTSRetina, 2009
- Apoptotic mechanisms within the retina in Staphylococcus epidermidis experimental endophthalmitisAlbrecht von Graefes Archiv für Ophthalmologie, 2008
- Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)British Journal of Ophthalmology, 2008
- Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Injections in An Office SettingAmerican Journal of Ophthalmology, 2008
- Role of Intravitreal Bevacizumab in Neovascular GlaucomaJournal of Ocular Pharmacology and Therapeutics, 2007